{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:59:30Z","timestamp":1792605570815,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2024.104261","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:08:21Z","timestamp":1733746101000},"page":"104261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Minimal residual disease in multiple myeloma"],"prefix":"10.1016","volume":"54","author":[{"given":"Nour","family":"Moukalled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lpm.2024.104261_bib0001","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.lpm.2024.104261_bib0002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/bmt.2014.326","article-title":"A multigene array for measurable residual disease detection in AML patients undergoing SCT","volume":"50","author":"Goswami","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.lpm.2024.104261_bib0003","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.lpm.2024.104261_bib0004","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2021012854","article-title":"Requirements for operational cure in multiple myeloma","volume":"138","author":"Mohty","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.lpm.2024.104261_bib0005","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.lpm.2024.104261_bib0006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"10.1016\/j.lpm.2024.104261_bib0007","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104261_bib0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cyto.b.21271","article-title":"Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service","volume":"90","author":"Rawstron","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"12","key":"10.1016\/j.lpm.2024.104261_bib0009","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.lpm.2024.104261_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.708231","article-title":"Ten color multiparameter flow cytometry in bone marrow and apheresis products for assessment and outcome prediction in multiple myeloma patients","volume":"11","author":"Riebl","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104261_bib0011","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jmoldx.2020.10.015","article-title":"Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry","volume":"23","author":"Ho","year":"2021","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1016\/j.lpm.2024.104261_bib0012","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lpm.2024.104261_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.lpm.2024.104261_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.lpm.2024.104261_bib0015","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104261_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104261_bib0017","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S2352-3026(21)00140-X","article-title":"Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy","volume":"8","author":"Bal","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104261_bib0018","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104261_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104261_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.lpm.2024.104261_bib0021","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10192","key":"10.1016\/j.lpm.2024.104261_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lpm.2024.104261_bib0023","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104261_bib0024","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2024.104261_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2024.104261_bib0026","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.lpm.2024.104261_bib0027","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three pethema\/gem clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104261_bib0028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104261_bib0029","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2024.104261_bib0030","series-title":"21st International Myeloma Society Annual Meeting; September 25-28","article-title":"Daratumumab SC + bortezomib\/lenalidomide\/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: results of the phase 3 CEPHEUS study","author":"Usmani","year":"2024"},{"key":"10.1016\/j.lpm.2024.104261_bib0031","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.lpm.2024.104261_bib0032","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.lpm.2024.104261_bib0033","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.lpm.2024.104261_bib0034","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104261_bib0035","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.lpm.2024.104261_bib0036","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/hemato5020012","article-title":"The role of autologous stem cell transplantation in the treatment of newly diagnosed multiple myeloma: is it time to rethink the paradigm in the era of targeted therapy?","volume":"5","author":"P","year":"2024","journal-title":"Hemato"},{"issue":"1","key":"10.1016\/j.lpm.2024.104261_bib0037","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","article-title":"Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma","volume":"14","author":"Martinez-Lopez","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"27","key":"10.1016\/j.lpm.2024.104261_bib0038","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.lpm.2024.104261_bib0039","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1016\/j.lpm.2024.104261_bib0040","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104261_bib0041","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.lpm.2024.104261_bib0042","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2023-185980","article-title":"Clinical significance of measurable residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients (Pts) treated with chimeric antigen receptor (CAR) t cells and t-cell engagers (TCE)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2024.104261_bib0043","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104261_bib0044","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.lpm.2024.104261_bib0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/2643-3230.BCD-23-0134","article-title":"MRD and plasma cell dynamics after CAR T-cell therapy in myeloma","volume":"4","author":"Landgren","year":"2023","journal-title":"Blood Cancer Discov"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549822400040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549822400040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:46:35Z","timestamp":1741027595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075549822400040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S075549822400040X"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104261","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104261"}}